Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat! - 2Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- 3Hungary's 'water guardian' farmers fight back against desertification
- 4Revvity says it will exceed 2025 profit forecast range
- 5WHO issues guidance on GLP-1 drugs for obesity
- Google to Use Natural Gas to Power Massive Data Center in Texas
- 'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- Scientists solve the mystery of the prehistoric 'Burtele Foot'
- The Golden Globes is happening Sunday: Who's nominated, who's hosting and how to watch
- The Most Astonishing Arising Advancements to Watch
- Surprising links between autism, Alzheimer’s could change how we treat both
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- BHP liable for 2015 Brazil mine disaster: UK court
- New York to require social media platforms to display mental health warnings
